Amylyx Pharmaceuticals (AMLX) Other Gross PP&E Adjustments (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) has 5 years of Other Gross PP&E Adjustments data on record, last reported at -$7.5 million in Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments fell 164.77% year-over-year to -$7.5 million; the TTM value through Dec 2025 reached -$7.5 million, down 164.77%, while the annual FY2025 figure was -$7.5 million, 164.77% down from the prior year.
- Other Gross PP&E Adjustments reached -$7.5 million in Q4 2025 per AMLX's latest filing, down from -$5.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $527000.0 in Q4 2021 and bottomed at -$7.5 million in Q4 2025.
- Average Other Gross PP&E Adjustments over 5 years is -$4.3 million, with a median of -$4.6 million recorded in 2023.
- Peak YoY movement for Other Gross PP&E Adjustments: plummeted 892.6% in 2022, then skyrocketed 61.38% in 2025.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $527000.0 in 2021, then tumbled by 892.6% to -$4.2 million in 2022, then increased by 23.32% to -$3.2 million in 2023, then rose by 11.11% to -$2.8 million in 2024, then plummeted by 164.77% to -$7.5 million in 2025.
- Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were -$7.5 million in Q4 2025, -$5.5 million in Q3 2025, and -$5.8 million in Q2 2025.